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Abstract
The outbreaks of West Nile virus (WNV), an emerging flavivirus recently implicated in outbreaks of fatal encephalitis, necessitate the
development of effective anti-WNV drugs. In this study, it is demonstrated that human serum albumin is transformed into a WNV antiviral
substance by hypochlorite (HOCl) modification. The HOCl-modified albumin efficiently neutralized WNV in vitro (EC50=300 nM) and showed
binding to a recombinant protein, representing the domain III of the WNV external envelope E glycoprotein.
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West Nile virus (WNV) belongs to the family Flaviviridae, a
large virus family that comprises more than 70 different viruses.
There is no specific treatment, drug or a vaccine available to
cure or prevent humans of WNV infection. In the recent years,
WNV outbreaks had been observed with significant rates of
mortality in humans (Vorou et al., 2007; CDC, 2007) and in
combination with its geographical expansion there is a pressing
need to develop WNV treatment options.
West Nile virions are spherical in shape (40–60 nm) and are
covered by a lipid envelope containing envelope proteins E
and M. In patients with WNV infection, neutralizing antibodies
can be detected (Niedrig et al., 2007; Planitzer et al., 2007),
which are preferentially directed against the E protein (Oliphant
et al., 2005). The E protein is divided into three domains where
antibodies binding to the domain III potently neutralize WNV in
vitro and in vivo (Oliphant and Diamond, 2007; Throsby et al.,
2007) in contrast to antibodies binding to other domains in the⁎ Corresponding author. Fax: +49 40 42818 378.
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doi:10.1016/j.virol.2007.12.008E protein (Throsby et al., 2006). Therefore, a recombinant pro-
tein representing domain III was principally used to detect the
antibody response in serum samples of WNV-infected indivi-
duals directed against domain III (Ludolfs et al., 2007). Since
domain III is a target for WNV-neutralizing antibodies and since
a peptide, representing the domain III sequence, can inhibit viral
infection (Chu et al., 2005), it is conceivable that this region
plays an important role in the entry process of WNV. These data
suggest that blocking domain III by a domain III-binding pro-
duct would efficiently inhibit viral infection.
Besides the specific humoral immune response, other non-
specific immune responses play a role in the defence against
pathogens. Such a non-specific immune response is provided by
neutrophils and eosinophils. Both cell types are packed with
peroxidases, with myeloperoxidase (MPO) being the most abun-
dant protein in the granules of neutrophils. Myeloperoxidase is
the central enzyme of the so-called MPO/H2O2/halide system
(Harrison and Schultz, 1976). The major product of the MPO/
H2O2/halide system is hypochlorite, which is generated by H2O2
oxidation of chloride. When neutrophils get activated, for ex-
ample by a soluble stimulus such as phorbol esters, formylated
peptides or cytokines, they undergo a process referred to as a
respiratory burst. During this process, the content of the granules
is released into phagolysosomes, but is also released into the
medium outside the cell. As a result, HOCl is present in the cell-
323M. Vossmann et al. / Virology 373 (2008) 322–328free environment able to kill pathogens but also able to modify
serum components.
In the past, it has been thought that HOCl acts directly against
pathogens based on its strong oxidative power (Klebanoff and
Coombs, 1992). In recent years, HOCl-modified components
were identified in blood and tissue (Marsche et al., 2007; Ham-
mer et al., 2001) using monoclonal antibodies directed against
HOCl-induced conformational changes (Gröne et al., 2002;
Malle et al., 1995) or directed against HOCl-induced modifica-
tions of amino acid residues (Gujral et al., 2004; Shao et al.,
2005).
Although the MPO enzyme as well as the chemical process
by which MPO is producing HOCl is very well characterized
(Klebanoff, 2005), the exact mechanism how microbial killing
occurs is still controversial. HOCl is thought to act directly
against pathogens as a toxic bleach. On the other hand, it is
conceivable that HOCl-modified components play an active part
in microbial inactivation.
Here in this study, HOCl-modified human serum albumin
(HSA) was generated and tested for its ability to neutralize WNVFig. 1. Neutralization ofWest Nile virus bymHSA.Cells were inoculatedwith virus su
medium. Infection of cells was monitored by a protein E-specific monoclonal antibod
2-phenylindol). (A) Vero B4 cells were infected with 6000 TCID50 of WNV. The mH
various concentrations (0, 10, 20, 40, and 80 μg/ml). (B) (− −): Vero B4 cells infected
infection and no mHSAwas added 1 h post infection. (− +): Cells were infected with
(80 μg/ml) was added to the infected cells. (+ −): Cells were incubated with WNV in t
no mHSA was added to the infected cells. (+ +): Cells were infected and mHSA (80in cell culture. We observed a potent inhibitory effect on WNV
infection (EC50=300 nM), whereas infection of cells byDengue-2
(DEN-2) and Yellow fever (YF) viruses remained unchanged.
Surface plasmon resonance (SPR) analysis demonstrated that
HOCl-modified HSA bound specifically to the WNVenvelope E
domain III, which was tested in form of a recombinant protein.
Thus, neutralization of WNV was clearly correlated with binding
of the inhibitor to the envelope E domain III.
Results and discussion
By using 6000 TCID50 ofWNVwe observed, that after 3 days
more than 98% of the Vero B4 cells were infected (Fig. 1A). This
infection rate was reduced to 53% bymHSA at 10 μg/ml; to 47%
by 20 μg/ml and to 30% by 40 μg/ml. No infected cells were
detected at 80 μg mHSA/ml. Thus, WNV infection could be
blocked by 50% with about 20 μg/ml of mHSA and a con-
centration of 80 μg mHSA/ml totally blocked infection. In these
experiments, infection was totally blocked when mHSA was
added to the cells together with virus supernatants. In the nextpernatants for 1 h. After 1 h, the virus supernatant was replaced against cell culture
y 3 days post infection. The cellular DNAwas stained by DAPI (4′,6-diamidino-
SA protein was present at time of infection and 1 h post infection until day 3 at
withWNV supernatant containing 1000 TCID50. No mHSAwas added at time of
out mHSA for 1 h. After 1 h, the cell culture medium was replaced and mHSA
he presence of mHSA (80 μg/ml). After 1 h the culture medium was replaced and
μg/ml) was present from time of infection until day 3.
Fig. 2. Effects of mHSA on cell proliferation and cell death. (A) 3H-Thymidine
incorporation assay. Vero B4 cells were cultured in 96-well plates in the
presence of mHSA (black) or HSA (white) at concentrations of 5, 20, 50, 100,
and 200 μg/ml. Each test was performed in triplicate. (B) TUNEL assay. Vero
B4 cells were cultured on 8-well chamber slides in the presence of 0, 300 and
600 μg/ml mHSA. TdT labeling with fluorescein-dUTP was performed on day
3. Cells were treated with DNase I as a positive control.
324 M. Vossmann et al. / Virology 373 (2008) 322–328experiment, we analyzed the effect of mHSA on viral spreading.
Vero B4 cells were inoculated with WNV supernatants for 1 h,
and after this period, cells were washed and the culture medium
was replaced. Thus, the effect of mHSA could now be tested in a
cell culture containing productively infected cells. As documen-
ted in Fig. 1B, aWNV dose representing 1000 TCID50 caused an
infection rate, on day 3, of about 63% (Fig. 1B; no mHSA
present; − −). When WNV was given to the cells for 1 h and the
medium was replaced by new medium containing 80 μg/ml
mHSA, the rate of infectionwas reduced to 22% (Fig. 1B;−+). No
infected cells were observed when mHSAwas present at the time
of infection (Fig. 1B; + +;+ −). The experiments document that
viral spreading in cell cultures, which were previously infected by
WNV, was efficiently blocked by mHSA (Fig. 1B; − +).
Next we have investigated the effect of mHSA on cell
proliferation and cell death (Fig. 2). In both assays, no negative
effect could be observed for concentrations that were 10 times
higher than the 50% inhibitory dose of about 20μgmHSA/ml. As
an additional control, we studied the viral growth of YF and
DEN-2 viruses in Vero B4 cells in the presence of mHSA. Firstly,
we studied viral entry by identification of virus antigen in an
immunofluorescence assay. Up to a final concentration of 160 μg
mHSA/ml we observed normal infection rates for DEN-2 and YF
viruses (Fig. 3A). Secondly, we have tested viral growth ofWNV,
DEN-2 andYF viruses, in the presence of 100μg/mlmHSA, over
a period of 9 days (Fig. 3B). Again, viral replication of DEN-2
andYFwas not reduced in the presence ofmHSA,whereasWNV
replication was completely blocked. Thus, mHSA was specific
againstWNVand no unspecific toxic side effect against Vero B4
cells, YF or DEN-2 viruses could be observed. Since the viral
growth of YF and DEN-2 was not inhibited, it is suggested that
mHSA will not inhibit the cellular metabolism or any other
intracellular mechanism needed to produce these viruses.
The experiments suggest that WNV infection is blocked at
the entry level. For WNV, the domain III of the E protein is
important for viral entry and since monoclonal antibodies
directed against this domain can block infection efficiently, we
have investigated the role of mHSA in binding to domain III. To
generate domain III, we have cloned its 101 amino acid coding
sequence into Escherichia coli expression vector pET22b and
expressed and purified it as a 6× His-tagged protein as docu-
mented in Fig. 4. To study domain III–mHSA interaction, we
used the method of surface plasmon resonance (SPR) spectro-
scopy. With this method, binding of a protein in solution to an
immobilized protein on a biosensor can be studied in real time.
We investigated domain III-to-mHSA binding in two ways.
Firstly, mHSA was immobilized on a biosensor and domain III
was studied for binding. Using this experimental design, we
observed strong binding of WNV domain III (Fig. 5A) and no
binding ofWNV domain III to a HSA coated biosensor (Fig. 5B)
or to the biosensor itself (data not shown). In addition to WNV
domain III we also tested recombinant domain III proteins of
DEN-2 and YF viruses for binding to mHSA. As documented in
Fig. 5E, the binding of DEN-2 and YF domain III was signi-
ficantly lower compared to the binding of WNV domain III to
mHSA. A comparison of the RU values for WNV domain III
binding (Fig. 5E) also showed that binding to immobilizedmHSAwas concentration dependent. Secondly, we have immo-
bilized domain III onto a biosensor and have now investigated
the binding of mHSA (Fig. 5C). In accordance with the first SPR
results, we observed again strong binding of mHSA to WNV
domain III. No binding of HSA to the immobilized WNV
domain III was observed (Fig. 5D). A comparison of the results
of the second experimental design (Fig. 5F) showed that mHSA
binding to immobilized WNV domain III was also specific as
well as concentration dependent. In the SPR study, the inter-
action between mHSA and the domain III of WNV was clearly
demonstrated, suggesting that mHSA inhibits infection by bind-
ing to the WNVenvelope E protein.
The modification of HSA by HOCl is a very complex chemi-
cal reaction and data on the modifications induced by HOCl are
Fig. 3. Effects of mHSA in YF and DEN-2 virus cultures. (A) Vero B4 cells were inoculated with (i) cell culture supernatants containing 1000 TCID50 of YF and DEN-2
virus and (ii) mHSA at various concentrations. After 1 h, the virus containing culture mediumwas replaced against medium containing the appropriate concentration of
mHSA. Virus-infected cells were detected on day 3 using a protein E-specific antibody. Cells, i.e. the cellular DNA, were stained by DAPI. (B) Replication kinetics of
WNV, DEN-2 and YF virus in the presence (black) and absence (white) of 100 μg/ml mHSA. Cells were infected at a multiplicity of infection of 0.1 with WNV
(squares), DEN-2 (triangles), YF (circles). After 1 h, the medium was replaced against medium containing the appropriate mHSA concentration. Virus titers were
measured by a plaque assay on days 1, 3, 5, 7 and 9.
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peptides (Hawkins et al., 2003). Various studies on protein HOCl
oxidation have shown that side-chainmodification, cross-linking
as well as fragmentation can be observed. However, Cys and
Met amino acids react most rapidly with HOCl (Pattison and
Davies, 2001), which can lead to cross-linking by the formation
of intra- and intermolecular sulfonamides (Fu et al., 2002).
Another known reaction of HOCl with proteins is the formation
of 3-chlorotyrosine and 3,5-dichlorotyrosine. Both chlorotyr-
osine species are used as markers for HOCl- or MPO-inducedreactions in vitro and in vivo (Kettle, 1996; Hazen and Heinecke,
1997). In a recently published study by Noueiry et al. (2007),
a secondary sulfonamid (AP30451) containing a 1-(3-chloro-
4-methylphenyl) group was identified as a new class of small
molecule inhibitors of WNV. We do not argue that HOCl-
modified serum albumins are a molecular mimicry of these small
molecular inhibitors, but HOCl treatment of serum albumins
seems to produce new functional groups which cause protein
binding activity for the WNV domain III and the chemical mo-
difications might be more specifically and not that randomized
Fig. 4. Expression and purification of the West Nile domain III. (A) Amino acid
sequence of the WNV domain III. Small letters, amino acids encoded by the
expression plasmid pET22b. (B) Polyacrylamide gel electrophoresis of His-tag
affinity-purified domain III protein.
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2006). Nonetheless, this study provides evidence for the hypo-
thesis that HOCl-induced oxidative changes in host proteins can
play an important role in the host defence against pathogens.
Materials and methods
Chemical modification of HSA
Human serum albumin was treated with hypochlorous acid
(HOCl) as described by Malle et al. (2000). In brief, HSA
(Sigma-Aldrich) was diluted in PBS pH 7.5 and HOCl was
added for 15 min at 4 °C. The molar ratio of HSA/HOCl was
1:500 and the HOCl concentration was controlled by UV spec-
troscopy (ε=375 mol/cm l). After incubation, the remaining
HOCl was separated by gel filtration (Sephadex G10) and con-
centrated by ultrafiltration (MWCO 10.000 D, Millipore) to a
final concentration of 10 mg/ml. The HSA protein treated with
a 500-fold molar surplus of HOCl was designated mHSA
(modified-HSA).
Effects of mHSA and HSA on Vero B4 cell proliferation
3H-Thymidine incorporation assay: Vero B4 cells (DSMZ
ACC 33, African green monkey kidney) were cultured in the
presence of mHSA or HSA at concentrations of 5, 20, 50, 100,
and 200 μg/ml. Vero B4 cells were seeded at 104 cells per well
in 96-well plates. Each test was performed in triplicate. On day
2, 0.2 μCi 3H-thymidine was added to each well. After 8 h, the
DNA was harvested, bound to a glass fibre membrane and
incorporated 3H-thymidine was monitored using a β-counter.
Direct TUNEL (terminal transferase dUTP nick end labeling)
assay: For the detection of mHSA-induced cell death, we used a
commercial kit (RocheApplied Science,USA) and performed the
assay according to the manufacturer's recommendations. Strand
breaks in cellular DNA present in apoptotic cells were labeled
with fluorescein-dUTP by the enzyme TdT (terminal deoxynu-
cleotidyl transferase). As a control, vital aswell asDNAse-treated
Vero B4 cells were tested to determine the background of apo-
ptotic cells under normal cell culture conditions.Neutralization of WNV by mHSA
Vero B4 cells were infected with WNV (strain Wengler,
SwissProt P06935, GenBank Accession Number M12294) and
infection was monitored by IFA using a glycoprotein E-specific
antibody. Cells were incubatedwith virus containing supernatants
(6000TCID50) for 1 h to allow infection. After this period, the cell
culture medium was replaced. The neutralization experiments
were different in the way mHSAwas added. Modified HSAwas
added to the cell cultures together with virus supernatants or
mHSA was added 1 h post infection. The infection of Vero B4
cells was monitored 3 days post infection by IF staining using the
glycoprotein E-specific mAb 15R4 (Ludolfs et al., 2002) and a
second anti-mouse FITC-conjugated antibody (Sigma-Aldrich,
USA). The experiments were carried out in 8-well glass slides
(chamber slide system; Nalge Nunc Int., USA).
As a control, Vero cells were infected with Yellow fever virus
(strain 17D; Theiler and Smith, 1937) or Dengue-2 Virus (strain
New Guinea C, GenBank Accession Number AF038403). Viral
infection by YF and Den-2 was detected 3 days post infection
using the YF protein E-specific mAb AK6330 (fromNiedrigM.,
Robert Koch Institute, Berlin, Germany) or a DEN-2 protein E
antibody-positive human serum sample (from Schmitz H.; Bern-
hard Nocht Institute, Hamburg).
Plaque assay
Serial dilutions of cell culture supernatants starting at 10−3
were given to Vero B4 cells grown on 6-well plates. After 1 h of
incubation, cells were washed and overlaid with 3 ml of medium
containing 0.5% agarose. After 7 days, 2ml of 7% formaldehyde
was added for 30 min. Overlays were removed and the cell
monolayer was stained using 0.5% crystal violet.
Expression and purification of the WNV domain III
The WNV domain III protein was generated as described
earlier (Ludolfs et al., 2007). In brief, domain III was cloned into
the E. coli expression vector pET22b and purified as a His-tagged
protein from E. coli lysates by Ni-nitrilotriaceticacid (NTA)
affinity chromatography in the presence of 7Murea. The 7Murea
solution containing the WNV domain III protein was loaded onto
a second Ni-NTA column. Bound protein was stepwise equi-
librated until the buffer concentration was 100 mM Tris pH 7.5.
Bound protein was eluted with Tris buffer (100 mM, pH 7.5)
containing imidazole (1 M). The eluted protein was directly
dialyzed against a PBS/20% glycerol solution. The final con-
centration of purified WNV domain III protein was 200 μg/ml.
Binding of mHSA to WNV domain III
Binding of mHSA to the domain III protein was moni-
tored by surface plasmon resonance (SPR; Biacore) spectro-
scopy. Human serum albumin was immobilized on a dextran-
coated, CH-activated C5 sensor chip (Biacore, Sweden) by NHS
(N-hydroxysuccinimide)/EDC (1-ethyl-3-(3-dimethylaminopro-
pyl)-carbodiimide hydrochloride) coupling at densities yielding
Fig. 5. mHSA binding to WNV domain III. Binding of domain III to immobilized mHSA (A, B, E) and binding of mHSA to immobilized domain III (C, D, F) was
monitored by surface plasmon resonance (SPR; Biacore) spectroscopy. Domain III and mHSAwere immobilized on a sensor chip (C5, Biacore, Sweden) at densities of
3900 or 3500 RU, respectively. Proteins were applied to the loaded sensor chips at a flow rates of 5 μl/min. Sensor grams shown in A to D represent RU differences
obtained frommeasurements of the mHSA or domain III loaded sensor and a non-loaded reference surface. (A) Overlay of sensor grams showing binding of domain III
protein to immobilized mHSA. Domain III was diluted in PBS/2 M urea and tested at concentrations of 50, 10 and 2 μg/ml (from top to bottom). (B) Same as in A, but
overlay of sensor grams showing HSA binding to immobilized mHSA. HSA concentrations: 2, 10, 50 and 250 μg/ml in PBS. (C) Overlay of sensor grams showing
binding of mHSA to immobilized domain III protein. mHSAwas tested at concentrations of 50, 10, 2 μg/ml PBS (from top to bottom). (D) Same as in C, but overlay of
sensor grams showing HSA binding to immobilized domain III protein. HSA concentrations: 2, 10, 50 and 250 μg/ml PBS. (E) Responses of WNV, DEN-2, YF
domain III and HSA tested against immobilized mHSA at the end of the association phase (600 s), domain III binding (black), HSA binding (white). (F) Responses of
mHSA and HSA tested against immobilized WNV domain III protein at the end of the association phase (600 s) as shown in C and D, mHSA binding (black), HSA
binding (white).
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328 M. Vossmann et al. / Virology 373 (2008) 322–3283500 response units (RUs). Sensor chips loaded with mHSA
were generated by treatment of a HSA-loaded sensor chip with a
PBS/HOCl solution (10 mM HOCl) for 10 min at RT. The
concentration of HOCl was monitored by UV spectroscopy
(ε=375 mol/cm l). The WNV domain III protein was immo-
bilized by NHS/EDC coupling on a C5 sensor chip at densities
yielding 3900 RUs. HSA and mHSA, diluted in PBS or domain
III proteins diluted in PBS/2 M urea, were applied to the loaded
sensor at a flow rate of 5 μl/min. Surface plasmon resonance
spectroscopy was carried out using a Biacore 1000. After each
test, the loaded sensorwas purified using 500μl of HCl (100mM)
at a flow rate of 100 μl/min.
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